These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20648600)

  • 1. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
    J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
    Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil.
    Silva AC; Spina AM; Lemos MF; Oba IT; Guastini Cde F; Gomes-Gouvêa MS; Pinho JR; Mendes-Correa MC
    Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):770-8. PubMed ID: 20944991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
    Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Hamet G; Martinot-Peignoux M; Matheron S; Marcellin P
    Liver Int; 2012 Jan; 32(1):93-101. PubMed ID: 22097898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
    Aghasadeghi MR; Bahramali G; Sadat SM; Farahani A; Mohraz M; Davar Siadat S; Mostafavi E; Memarnejadian A; Ardestani MS; Vahabpour R; Saraji AA; Delbaz SA
    Curr HIV Res; 2011 Jun; 9(4):263-9. PubMed ID: 21671883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.